Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib Abstract #2948

Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.
Aim(s): To develop and validate a computed tomography (CT) based method to predict the efficacy of sunitinib in patients with pancreatic neuroendocrine tumors (panNET).
Materials and methods: Pretreatment contrast-enhanced computed tomography from panNET patients collected from multi-centers was used.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Professor Jie Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, Li Z P, Feng S T
#1468 Evaluation of ENETS and AJCC Staging Systems for Pancreatic Neuroendocrine Neoplasms: A Multicenter Study in China.
Introduction: Accurate staging system is crucial for p-NENs management. The European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/ American Joint Cancer Committee/ World Health Organization (UICC/AJCC/WHO) advocated their TNM staging system for pancreatic neuroendocrine neoplasms (p-NENs) respectively.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Dr Kaizhou Jin
Authors: Jin K, Zhang Y, Luo G, Sun J, ...
#846 Effects of Sunitinib in Combination with Octreotide LAR for Patients with Advanced Pancreatic Neuroendocrine Tumor which Failed Sunitinib or Octreotide LAR Alone
Introduction:
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Chunmei Bai
Authors: Ying H, Cheng Y, Sun Z, Xue H, ...
#1439 Sunitinib in the Treatment of Unresectable or Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm: A Multicenter Retrospective Study in China
Introduction: Sunitinib has shown activity against pancreatic neuroendocrine tumors(NEN) in a global phase III clinical trial.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Chen Jie
#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia
Authors: Jia R, Li Y L, Jin Y S, Chen Y, ...